◎ Sugi Atlas

Atlas / Drug / Fludarabine Phosphate

Fludarabine Phosphate

drug
On this page

Also known as FludaraFludarabine 5'-monophosphateFludarabine monophosphateNSC-312887NSC-328002OfortaFludarabinefludarabine-phosphateFludarabine phosphateÊFludarabine phosphateÂ

Summary

Fludarabine Phosphate (CHEMBL1096882) is an approved small-molecule antineoplastic agent (ATC L01BB05); indicated across 91 conditions including b-cell chronic lymphocytic leukemia and neoplasm; with CIViC clinical evidence for 1 variant-indication association (e.g. IKZF1 Deletion in b-lymphoblastic leukemia/lymphoma).

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Small molecule
  • ATC class: L01BB05
  • Indications: 91 conditions
  • Clinical trials: 1,556
  • Precision-oncology evidence (CIViC): 1 variant–indication association
  • Chemistry: 365.21 Da · C10H13FN5O7P

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL1096882
NameFludarabine Phosphate
TypeSmall molecule
Max phase4
FDA approvedyes
PubChem CID30751
ChEBICHEBI:63599
ATCL01BB05
Molecular formulaC10H13FN5O7P
Molecular weight365.21
InChIKeyGIUYCYHIANZCFB-FJFJXFQQSA-N

SMILES: C1=NC2=C(N=C(N=C2N1[C@H]3[C@H]([C@@H]([C@H](O3)COP(=O)(O)O)O)O)F)N

IUPAC name: [(2R,3S,4S,5R)-5-(6-amino-2-fluoropurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate

ChEBI definition: A purine arabinonucleoside monophosphate having 2-fluoroadenine as the nucleobase. A prodrug, it is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. Once incorporated into DNA, 2-fluoro-ara-ATP functions as a DNA chain terminator. It is used for the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to, or whose disease has progressed during, treatment with at least one standard alkylating-agent containing regimenas.

Pharmacological roles (ChEBI): antineoplastic agent, immunosuppressive agent, antiviral agent, prodrug, DNA synthesis inhibitor.

Other ChEBI roles (chemical / environmental): antimetabolite.

Also known as: Fludara, Fludarabine 5’-monophosphate, Fludarabine monophosphate, Fludarabine phosphate, NSC-312887, NSC-328002, Oforta, Fludarabine Phosphate, FLUDARABINE PHOSPHATE, Fludarabine, fludarabine-phosphate, Fludarabine phosphateÊ

Patent coverage: 29,805 distinct patent families (120,716 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 120,496 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Carbonic anhydrase 5A, mitochondrial.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 1 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

TargetpChemblTypeValueUnitActivity ID
CA5A6.88Ki130.9nMCHEMBL_ACT_19073672

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

91 indications (3 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
B-cell chronic lymphocytic leukemia4MONDO:0004948EFO:0000095
neoplasm4MONDO:0005070EFO:0000616
lymphoma3MONDO:0005062EFO:0000574
acute myeloid leukemia3MONDO:0018874EFO:0000222
acute lymphoblastic leukemia3MONDO:0004967EFO:0000220
aplastic anemia3MONDO:0015909HP:0001915
neoplasm of mature B-cells3MONDO:0004949EFO:0000096
Hodgkins lymphoma3MONDO:0004952EFO:0000183
myelodysplastic syndrome3MONDO:0018881EFO:0000198
chronic myeloid leukemia3MONDO:0011996EFO:0000339
diffuse large B-cell lymphoma3MONDO:0018905EFO:0000403
leukemia3MONDO:0005059EFO:0000565
plasma cell myeloma3MONDO:0009693EFO:0001378
myelodysplastic syndrome with single lineage dysplasia3MONDO:0005272EFO:0003802
mantle cell lymphoma3MONDO:0018876EFO:1001469
acute megakaryoblastic leukemia3MONDO:0018872EFO:0003025
Waldenstrom macroglobulinemia3MONDO:0100280EFO:0009441
chronic myelomonocytic leukemia3MONDO:0020311EFO:1001779
acute erythroid leukemia3MONDO:0017858EFO:0000218
acute monocytic leukemia3MONDO:0007896EFO:0000221
acute myelomonocytic leukemia M43MONDO:0018871EFO:0000223
myeloproliferative neoplasm3MONDO:0020076EFO:0002428
acute myeloblastic leukemia without maturation3MONDO:0005224EFO:0003027
myelodysplastic syndrome with excess blasts3MONDO:0019454EFO:0003811
follicular lymphoma3MONDO:0018906MONDO:0018906
sarcoma2MONDO:0005089EFO:0000691
lymphoid leukemia2MONDO:0005402EFO:0004289
cutaneous melanoma2MONDO:0005012EFO:0000389
Crohn disease2MONDO:0005011EFO:0000384
neuroblastoma2MONDO:0005072EFO:0000621
systemic sclerosis2MONDO:0005100EFO:0000717
melanoma2MONDO:0005105EFO:0000756
lymphoid neoplasm2MONDO:0005157EFO:0001642
primary myelofibrosis2MONDO:0009692EFO:0002430
metastatic melanoma2MONDO:0005191EFO:0002617
breast neoplasm2MONDO:0021100EFO:0003869
non-Hodgkin lymphoma2MONDO:0018908EFO:0005952
B-cell prolymphocytic leukemia2MONDO:0019461EFO:1000102
juvenile myelomonocytic leukemia2MONDO:0011908EFO:1000309
T-cell prolymphocytic leukemia2MONDO:0019468EFO:1000560
Sezary syndrome2MONDO:0017844EFO:1000785
mycosis fungoides2MONDO:0009691EFO:1001051
histiocytosis2MONDO:0002637HP:0100727
peripheral T-cell lymphoma, not otherwise specified2MONDO:0004964EFO:0000211
angioimmunoblastic T-cell lymphoma2MONDO:0004977EFO:0000255
Burkitt lymphoma2MONDO:0007243EFO:0000309
acquired polycythemia vera2MONDO:0009891EFO:0002429
anaplastic large cell lymphoma2MONDO:0020325EFO:0003032
MALT lymphoma2MONDO:0007650EFO:0000191
prolymphocytic leukemia2MONDO:0001023MONDO:0001023
peritoneal neoplasm2MONDO:0006901MONDO:0002087
fallopian tube neoplasm2MONDO:0021092MONDO:0002158
kidney cancer2MONDO:0002367MONDO:0002367
ovarian cancer2MONDO:0008170MONDO:0008170
graft versus host disease2MONDO:0013730MONDO:0013730
nasal cavity and paranasal sinus lethal midline granuloma2MONDO:0006828MONDO:0019472
hematopoietic and lymphoid system neoplasm2MONDO:0002334MONDO:0044881
skin neoplasm2MONDO:0002531MONDO:0002898
myelodysplastic/myeloproliferative disease2MONDO:0020077MONDO:0020077
Wiskott-Aldrich syndrome2MONDO:0010518MONDO:0010518
sickle cell disease2MONDO:0011382MONDO:0011382
Diamond-Blackfan anemia2MONDO:0015253MONDO:0015253
severe combined immunodeficiency2MONDO:0015974MONDO:0015974
osteopetrosis2MONDO:0017198MONDO:0017198
Fanconi anemia2MONDO:0019391MONDO:0019391
systemic lupus erythematosus2MONDO:0007915MONDO:0007915
hemoglobinuria2MONDO:0003656MONDO:0100244
plasma cell neoplasm2MONDO:0004959EFO:0000200
B-cell acute lymphoblastic leukemia1MONDO:0004947EFO:0000094
renal cell carcinoma1MONDO:0005086EFO:0000681
plasma cell leukemia1MONDO:0018689EFO:0006475
head and neck cancer1MONDO:0005627EFO:0006859
metastatic prostate carcinoma1MONDO:0004956EFO:0000196
metastatic neoplasm1MONDO:0024883EFO:0009709
blast phase chronic myelogenous leukemia, BCR-ABL1 positive1MONDO:0006115EFO:1000131
acute biphenotypic leukemia1MONDO:0020322MONDO:0019460
multiple sclerosis1MONDO:0005301MONDO:0005301
prostate carcinoma1MONDO:0005159EFO:0001663

13 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 1,556.

Phase distribution

PhaseTrials
PHASE2561
PHASE1473
PHASE1/PHASE2269
PHASE389
Not specified77
EARLY_PHASE144
PHASE2/PHASE325
PHASE418

Top trials by phase / activity

NCTPhaseStatusTitle
NCT00198991PHASE4COMPLETEDGerman Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003)
NCT00199056PHASE4COMPLETEDGerman Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (06/99)
NCT00199147PHASE4UNKNOWNEfficacy of G-CSF-Priming in Elderly AML Patients
NCT00220311PHASE4COMPLETEDA Study to Confirm the Efficacy and Safety of Fludarabine Phosphate Administered in Untreated Chronic Lymphocytic Leukemia Patients With Anemia and/or Thrombocytopenia
NCT00361140PHASE4COMPLETEDBusulfan Safety/Efficacy as Conditioning Prior to Hematopoietic Cell Transplantation (HCT)
NCT00487448PHASE4COMPLETEDSMD_FLAG-IDA_98: FLAG-IDA in Induction Treatment of High Risk Myelodysplastic Syndromes or Secondary Acute Myeloblastic Leukemia
NCT00488709PHASE4COMPLETEDFludarabine, Cytarabine, Topotecan in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
NCT01088724PHASE4COMPLETEDFludarabine, Cyclophosphamide, Doxorubicin and Rituximab for the Treatment of Post-transplant Lymphoproliferative Disease (PTLD)
NCT01271010PHASE4TERMINATEDA Study of Rituximab in Combination With Fludarabine and Cyclophosphamide in Participants With Chronic Lymphocytic Leukemia and Favorable Somatic Status
NCT01283386PHASE4TERMINATEDA Study to Compare Mabthera (Rituximab), Fludarabine and Cyclophosphamide to Mabthera and Chlorambucil in Participants With Chronic Lymphocytic Leukemia and Unfavorable Somatic Status
NCT02024308PHASE4UNKNOWNAML1-ETO Acute Myeloid Leukemia With Fludarabine and Cytarabine Chemotherapy
NCT02784561PHASE4UNKNOWNStudy of Busulfan and FLAG Conditioning Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation
NCT02894645PHASE4UNKNOWNMalaysia-Singapore Acute Lymphoblastic Leukemia 2010 Study
NCT02926586PHASE4COMPLETEDFludarabine and Cytarabine Versus High-dose Cytarabine for CBF-AML
NCT03171831PHASE4UNKNOWNHaploidentical Hematopoietic Stem Cell Transplantation for Patients With Thalassemia Major
NCT04009525PHASE4COMPLETEDHematopoietic Stem Cell Transplantation for Patients With Thalassemia Major: A Multicenter, Prospective Clinical Study
NCT05108805PHASE4COMPLETEDChimeric Antigen Receptor (CAR) T Cell Therapy With YESCARTA in the Outpatient Setting
NCT05379569PHASE4UNKNOWNComparative Study of BFC and BuCy Conditioning Regimen for Allo-PBSCT in Acute B-cell ALL
NCT01949129PHASE2/PHASE3RECRUITINGAllogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia
NCT02048813PHASE3ACTIVE_NOT_RECRUITINGIbrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT02724163PHASE3RECRUITINGInternational Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia
NCT03182244PHASE3ACTIVE_NOT_RECRUITINGA Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase 3 (FLT3) Mutation
NCT03480360PHASE3ACTIVE_NOT_RECRUITINGHaploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators’ Expression
NCT03643276PHASE3RECRUITINGTreatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017
NCT03937544PHASE2/PHASE3RECRUITINGIntravenous Autologous CD19 CAR-T Cells for R/R B-ALL
NCT04217278PHASE2/PHASE3ACTIVE_NOT_RECRUITINGA Trial of Treatments to Assess the Effects on Outcome of Adults With AML and MDS Undergoing Allogeneic SCT
NCT04708054PHASE2/PHASE3RECRUITINGVenetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS
NCT04923893PHASE3ACTIVE_NOT_RECRUITINGA Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy
NCT05183035PHASE3RECRUITINGVenetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
NCT05257083PHASE3ACTIVE_NOT_RECRUITINGA Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma
NCT05371093PHASE3ACTIVE_NOT_RECRUITINGStudy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma
NCT05457556PHASE3ACTIVE_NOT_RECRUITINGMismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome
NCT05600426PHASE3ACTIVE_NOT_RECRUITINGA Trial Comparing Unrelated Donor BMT With IST for Pediatric and Young Adult Patients With Severe Aplastic Anemia (TransIT, BMT CTN 2202)
NCT05605899PHASE3ACTIVE_NOT_RECRUITINGStudy to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma
NCT05624554PHASE3ACTIVE_NOT_RECRUITINGA Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)
NCT05674539PHASE3ENROLLING_BY_INVITATIONReduced Intensity Conditioning Regimens for Acute Myeloid Leukemia and Myelodysplastic Syndrome
NCT05991908PHASE3RECRUITINGRandomized Study of Conditioning of Fludarabine Combined With Single or Dual Alkylating Agents in Myeloid Malignancies
NCT06045806PHASE3ACTIVE_NOT_RECRUITINGA Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation
NCT06297772PHASE3NOT_YET_RECRUITINGCompare the Efficacy and Safety of Dec-FB4 and FB4 as Conditioning Regimen for AML-MR
NCT06319456PHASE3RECRUITINGA Global Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.

Clinical evidence (CIViC)

Variant × indication × effect (1 predictive associations from 1 curated evidence items):

VariantIndicationEffectTherapyLevelCIViC
IKZF1 DeletionB-lymphoblastic Leukemia/lymphomaSensitivity/ResponseMethotrexate + Daunorubicin + Cytarabine + Fludarabine + ImatinibCIViC BEID7366

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline, but PharmGKB curates 6 clinical and 12 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 16

This page pulls from 16 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclinical_trialsefogtopdb_ligandhgncmeshmondopatent_compoundpharmgkbpharmgkb_guidelinepubchemuniprot